Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study

NCT01907607 is registered in ClinicalTrials.gov with Institut Bergonié as lead sponsor.

NCT NCT01907607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01907607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of PD-0332991 in Patients With Advanced Gastrointestinal Stromal Tumors Refractory to Imatinib and Sunitinib: A Phase 2 Study
Lead sponsor
Institut Bergonié
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2014
Completion date
February 28, 2019
Enrollment
29 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastrointestinal stromal tumors